| Title |
Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation
|
|---|---|
| Published in |
BMC Neurology, February 2012
|
| DOI | 10.1186/1471-2377-12-2 |
| Pubmed ID | |
| Authors |
Susanne Hartz, Denis Getsios, Sunning Tao, Steve Blume, Grant Maclaine |
| Abstract |
Previous cost-effectiveness studies of cholinesterase inhibitors have modeled Alzheimer's disease (AD) progression and treatment effects through single or global severity measures, or progression to "Full Time Care". This analysis evaluates the cost-effectiveness of donepezil versus memantine or no treatment in Germany by considering correlated changes in cognition, behavior and function. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 105 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | <1% |
| Brazil | 1 | <1% |
| Unknown | 103 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 27 | 26% |
| Student > Ph. D. Student | 15 | 14% |
| Student > Master | 12 | 11% |
| Student > Bachelor | 7 | 7% |
| Student > Doctoral Student | 6 | 6% |
| Other | 17 | 16% |
| Unknown | 21 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 23 | 22% |
| Economics, Econometrics and Finance | 12 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 5% |
| Business, Management and Accounting | 5 | 5% |
| Agricultural and Biological Sciences | 5 | 5% |
| Other | 26 | 25% |
| Unknown | 29 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 February 2012.
All research outputs
#18,304,230
of 22,662,201 outputs
Outputs from BMC Neurology
#1,873
of 2,409 outputs
Outputs of similar age
#197,171
of 247,686 outputs
Outputs of similar age from BMC Neurology
#11
of 14 outputs
Altmetric has tracked 22,662,201 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,409 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.8. This one is in the 12th percentile – i.e., 12% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 247,686 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 9th percentile – i.e., 9% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one is in the 7th percentile – i.e., 7% of its contemporaries scored the same or lower than it.